Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

On location

Late-Breaking Abstracts Address Thrombosis and COVID-19

A growing body of clinical evidence indicates that COVID-19 infection predisposes patients to arterial and venous thrombosis and thrombotic complications. At the International Society...
On location

Extended Half-Life Factor VIII Fusion Protein Effective in Previously Untreated Hemophilia A

The use of extended half-life recombinant factor VIII Fc fusion protein (rFVIIIFc) appeared to be safe and effective in young boys with previously untreated...
On location

FLT180a: A New Gene Therapy Candidate for Severe Hemophilia B

In a small study of patients with severe hemophilia B, the novel adeno-associated virus (AAV) gene therapy FLT180a was associated with increased factor IX...
On location

Decitabine Plus Venetoclax Outperforms Intensive Chemotherapy Across Risk Groups

For older and unfit patients with acute myeloid leukemia (AML), venetoclax plus hypomethylating agents (HMAs) have been established as a standard of care and...
On location

Phase I Trial Supports CC-92480 for Heavily Pretreated Myeloma

Results from a first-in-human trial of CC-92480 in patients with relapsed or refractory multiple myeloma show a manageable safety profile and promising efficacy, according...
On location

Caplacizumab Produces Faster, Sustained Platelet Count Responses Than Placebo in aTTP

Patients with acquired thrombotic thrombocytopenic purpura (aTTP) who were treated with caplacizumab – anti–von Willebrand factor humanized immunoglobulin – experienced a faster and more...
On location

Isatuximab Plus Carfilzomib: A New Standard for Relapsed/Refractory Myeloma?

The three-drug combination of the CD38-targeting antibody isatuximab plus carfilzomib and dexamethasone significantly improved progression-free survival (PFS) in patients with relapsed or refractory multiple...
On location

Idecabtagene Vicleucel Demonstrates Deep, Durable Responses in Relapsed/Refractory Myeloma

The BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel (previously known as bb2121) induced responses in nearly three-quarters of patients with relapsed/refractory multiple...
On location

ANDROMEDA: Subcutaneous Daratumumab for Newly Diagnosed Light Chain Amyloidosis

Adding subcutaneous daratumumab to the combination of cyclophosphamide, bortezomib, and dexamethasone (CyBorD) resulted in deeper and more rapid hematologic responses and improved clinical outcomes,...
On location

A New CAR T-Cell Target for T-Cell Acute Lymphocytic Leukemia?

The anti-CD7 chimeric antigen receptor (CAR) T-cell therapy TruUCAR GC027 demonstrated promising efficacy in treating adults with relapsed or refractory T-cell acute lymphoblastic leukemia...
Advertisement

Current Issue

September 2020 Volume 6, Issue 11

This issue features a look at the evolution of preprint platforms, an analysis of the economic and health consequences of the COVID-19 pandemic, and more.

Block title